Today: 31 January 2026
Subscribe
Browse Category

NYSE:FYBR News 21 December 2025 - 1 January 2026

Verizon stock today: VZ ends 2025 nearly flat as investors circle Jan. 30 earnings, dividend dates

Verizon stock today: VZ ends 2025 nearly flat as investors circle Jan. 30 earnings, dividend dates

NEW YORK, December 31, 2025, 20:03 ET — Market closed Verizon Communications Inc. shares finished the year’s final trading session little changed on Wednesday, closing up 0.1% at $40.73 after trading between $40.67 and $40.96. Verizon’s investor relations site lists a fourth-quarter earnings webcast for Jan. 30 at 8:00 a.m. ET. The late-January report is the next major catalyst for…
1 January 2026
·······
Verizon Stock (VZ) News Today: Frontier Deal Approvals, 5G Tower Partnership, Dividend Outlook and 2026 Catalysts (Dec. 21, 2025)

Verizon Stock (VZ) News Today: Frontier Deal Approvals, 5G Tower Partnership, Dividend Outlook and 2026 Catalysts (Dec. 21, 2025)

Verizon Communications Inc. (NYSE: VZ) heads into the final full trading week of 2025 with investors focused on two big themes: the march toward closing its Frontier Communications acquisition and the company’s push to keep network investment efficient while protecting cash flow. With U.S. markets closed on Sunday, December 21, 2025, the most recent trading print reflects Friday’s session, when…
21 December 2025
····

Stock Market Today

  • Travere Therapeutics (TVTX) Shows Potential Undervaluation Amid Volatile Share Price
    January 31, 2026, 3:27 PM EST. Travere Therapeutics (TVTX) has experienced volatile price swings, with a recent 5.6% gain over seven days but an 18.6% drop over 30 days. Its 52% return over the past year underscores strong long-term performance. A Discounted Cash Flow (DCF) analysis indicates the shares are trading at a 73.6% discount to intrinsic value, suggesting potential undervaluation. Despite recent losses in free cash flow, projections show significant improvement by 2030. Price to Sales (P/S) ratios also provide insight given the company's fluctuating profits. Investors should weigh these factors carefully as the company operates in the competitive biotech and pharmaceuticals sector, where pipeline and commercial outlook heavily influence sentiment and valuation.
Go toTop